Veraxa Biotech AG - Post de-SPAC

VRXA chart

Veraxa Biotech AG - Post de-SPAC news

• At $1.09 a share, director Ziegler buys 30,000 Veraxa Biotech (VRXA) shares.

  Stock Titan · Oct 21, 4:19 PM EDT

• VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline

  Yahoo Finance · Oct 21, 3:00 PM EDT

• Form 4 Veraxa Biotech AG - Post de-SPAC: Christoph Samuel Ziegler (Director) For: 20 October

  Investing.com Nigeria · Oct 21, 3:00 AM EDT

• VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

  Yahoo Finance · Oct 13, 3:30 PM EDT

• VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

  Yahoo Finance · Oct 13, 7:00 AM EDT

• VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

  Yahoo Finance · Oct 7, 3:00 PM EDT

• This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

  Yahoo Finance · Oct 7, 9:58 AM EDT

• Veraxa Biotech stock gains on FDA-aligned testing strategy

  Yahoo Finance · Oct 7, 9:29 AM EDT

• VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

  Yahoo Finance · Oct 7, 7:00 AM EDT

• VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress

  Yahoo Finance · Sep 24, 3:38 PM EDT

• VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

  Yahoo Finance · Sep 22, 2:30 PM EDT

• VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

  Yahoo Finance · Sep 18, 3:30 PM EDT

Veraxa Biotech AG - Post de-SPAC key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-K6-K2026-10-15
• 6-K6-K2026-09-04
• 6-K6-K2026-08-24
• 6-K6-K2026-07-31
• 6-K6-K2026-07-27
• 6-K6-K2026-07-27
• 6-K6-K2026-06-18
• 20-F20-F2026-06-16
• 6-K6-K2026-06-11

About Veraxa Biotech AG - Post de-SPAC

Ticker

VRXA (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Zurich

Incorporated in

Switzerland

Fiscal year end

December 31

SEC CIK

2079109

Former names

Veraxa Biotech Holding AG

Frequently asked questions